Two days of oatmeal cuts bad cholesterol by 10 percent

A clinical trial from the University of Bonn shows that consuming mostly oatmeal for two days can reduce harmful LDL cholesterol by 10 percent in people with metabolic syndrome. The benefits, including changes in gut bacteria, persisted for six weeks. Participants also experienced modest weight loss and lower blood pressure.

Researchers at the University of Bonn conducted a randomized controlled trial published in Nature Communications, examining the effects of a short-term oat-based diet on individuals with metabolic syndrome. This condition involves excess body weight, high blood pressure, elevated blood sugar, and abnormal lipid levels, increasing risks for heart disease and diabetes.

In the study, 32 participants followed a 48-hour calorie-restricted plan consisting almost entirely of oatmeal, consuming 300 grams per day boiled three times daily with minimal additions like fruit or vegetables. This halved their usual calorie intake. A control group reduced calories similarly but without oats.

Both groups saw some improvements from calorie reduction, but the oatmeal group experienced stronger effects. "The level of particularly harmful LDL cholesterol fell by 10 percent for them -- that is a substantial reduction, although not entirely comparable to the effect of modern medications," said Marie-Christine Simon, junior professor at the University of Bonn's Institute of Nutritional and Food Science. Participants in this group lost an average of two kilograms and had slight drops in blood pressure.

The LDL reduction remained noticeable six weeks later. Analysis revealed shifts in the gut microbiome, with increased bacteria producing phenolic compounds like ferulic acid, which may influence cholesterol metabolism positively. "We were able to identify that the consumption of oatmeal increased the number of certain bacteria in the gut," noted lead author Linda Klümpen.

A follow-up six-week phase with 80 grams of oatmeal daily without calorie limits yielded only modest changes, suggesting intensive short-term consumption is more effective. Simon suggested periodic oat-based diets could help maintain cholesterol levels and prevent diabetes, though further research is needed.

The trial involved 68 participants total, with measurements of blood, stool, weight, and blood pressure taken before, immediately after, and at intervals up to six weeks. Funding came from sources including the German Federal Ministry of Education and Research.

Labaran da ke da alaƙa

Illustration of a study participant with brain scans and gut bacteria visuals related to intermittent fasting research.
Hoton da AI ya samar

Intermittent energy restriction tied to shifts in brain activity and gut microbiome, small study suggests

An Ruwaito ta hanyar AI Hoton da AI ya samar An Binciki Gaskiya

A small 2023 study of adults with obesity in China found that an intermittent energy restriction program was associated with weight loss and changes in gut bacteria alongside altered activity in brain regions linked to appetite, cravings and self-control.

A major Spanish clinical trial has shown that a modified Mediterranean diet, combined with calorie restriction, physical activity and professional support, reduced the risk of type 2 diabetes by 31 percent over six years. The findings come from the PREDIMED-Plus study involving nearly 5,000 adults with overweight or obesity.

An Ruwaito ta hanyar AI

A large international study has found that fewer than one in five people consume enough flavanols to gain heart health benefits, even when meeting standard fruit and vegetable guidelines.

A Stanford Medicine-led randomized trial in the United States found that a five-day-per-month fasting-mimicking diet was linked to improved patient-reported symptoms and lower biological markers of inflammation in adults with mild-to-moderate Crohn’s disease. The results were published in Nature Medicine.

An Ruwaito ta hanyar AI

Researchers from Mass General Brigham found that the cholesterol drug evolocumab cuts the risk of first-time major cardiovascular events by 31% in high-risk patients with diabetes who lack diagnosed atherosclerosis. The results, from a subgroup analysis of the VESALIUS-CV trial, were presented at the American College of Cardiology's Annual Scientific Session and published in JAMA. Patients on the drug saw LDL cholesterol levels drop significantly alongside standard treatments.

Wannan shafin yana amfani da cookies

Muna amfani da cookies don nazari don inganta shafin mu. Karanta manufar sirri mu don ƙarin bayani.
Ƙi